|Market Cap (Intraday)||1.07B|
|2yr Forward PE||N/A|
Icosavax Inc Stock, NASDAQ:ICVX
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses in developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.